

BioDuro enters Taiwan joint venture to expand resilient global API manufacturing capacity

March 9, 2026 | News

BioDuro's strengths in early-stage drug development integrated with Cenra's expertise in commercial scale GMP API manufacturing



US-based BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), has established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech (CCSB), a leading pharmaceutical chemical manufacturer in Taiwan since 1964, to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra's campus in Taipei, Taiwan, to BioDuro's global network.

The joint venture will see BioDuro's strengths in early-stage drug development integrated with Cenra's expertise in commercial scale GMP API manufacturing, providing global clients with an end-to-end API solution from early development through to commercial-scale manufacturing.

The Taipei campus houses 10 GMP API production lines with a total reactor volume of more than 350,000 liters to support annual API output of up to 200 metric tons. The facility has been successfully inspected by several major international regulatory agencies, including the US FDA, EMA, Japan's PMDA, and Taiwan's TFDA.

"By combining BioDuro's integrated CMC expertise with Cenra's nearly six decades of GMP manufacturing excellence and enviable international regulatory history, our joint venture strengthens both companies' global supply chain resilience and minimises the risks of technology-transfers," said Armin Spura, Ph.D., CEO of BioDuro.

"BioDuro serves more than 1,500 global customers annually with industry-leading R&D and manufacturing capabilities," added Wayne Hsiao, President of Cenra API Solutions.